ALGN vs DFTX
Align Technology vs Definium Therapeutics, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
DFTX
Definium Therapeutics, Inc.
62
Buy
| Metric | ALGN | DFTX |
|---|
| AI Score |
73
|
62
|
| Price |
$172.86
|
$40.91
|
| P/E Ratio |
30.03×
|
-11.89×
|
| ROE |
10.1%
|
-55.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
0.0%
|
| Debt / Equity |
0.03×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
36.3
|
| Beta |
1.653
|
2.237
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus DFTX.
ALGN leads by 11 points.
ALGN scores 73/100 (Buy) versus DFTX at 62/100 (Buy).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
DFTX Committee View
60% agreement
5 analysts
Positive signals support the current rating — low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.0x prices in significant intangible value — Value
- ROE of only -85.2% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical